

AZD-5153

4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-**ALTERNATE NAME:**

dimethylpiperazin-2-one, 6-hydroxynaphthalene-2-carboxylic acid

B2020-5 CATALOG #:

B2020-25

5 mg AMOUNT: 25 mg

STRUCTURE:

MOLECULAR FORMULA: $C_{25}H_{33}N_7O_3\cdot C_{11}H_8O_3$

MOLECULAR WEIGHT: 667.8

CAS NUMBER: 1869912-40-2

Crystalline solid APPEARANCE:

DMSO SOLUBILITY:

PURITY: >98% by HPLC

STORAGE: Store at -20°C; Protect from air and light

DESCRIPTION: AZD-5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor with a bivalent

binding mode. AZD-5153 ligates two bromodomains in BRD4 simultaneously. Displays cellular and

antitumor activity in preclinical hematologic tumor models.

RELATED PRODUCTS:

I-BET151 (Cat. No. 2220-1, 5) Bromodomain Inhibitor, (+)-JQ1 (Cat. No. 2070-1, 5) AZD-5153 (Cat. No. B2020-5,25) SGI-1027 (Cat. No. 2726-5, 25) EZSolution™ (+)-JQ1 (Cat. No. 2091-1) Lomeguatrib (Cat. No. 2224-5, 25 ARV-825 (Cat. No. B2019-1,5) Mivebresib (Cat. No. B1564-5,25) BRD4770 (Cat. No.9525-5, 25)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure.